TORONTO (MedPage Today) -- Adding the fourth-generation fluoroquinolone moxifloxacin (Avelox) to standard tuberculosis therapy may allow treatment times to be shortened, an international study suggests.
Novel TB Regimen May Allow Shorter TreatmentCourtesy MedPage Today Infectious Disease Thu, 04/02/2009 - 16:30
TORONTO (MedPage Today) -- Adding the fourth-generation fluoroquinolone moxifloxacin (Avelox) to standard tuberculosis therapy may allow treatment times to be shortened, an international study suggests. More related itemsTB-Infected Trainee Prompts Scare in Chicago
CDC Urges Nucleic Acid Amplification Testing for All...
ACAAI: Primary Immunodeficiency Is Surprisingly Common
Jennifer Gianni's Fusion Pilates for Post Pregnancy &...
Homedics SBM-200H Therapist Select Shiatsu Massaging...
|
Popular by tags WeekMonth |
Post new comment